1792181-33-9

1792181-33-9 structure

Name: Vunakizumab
Chemical Name: Vunakizumab
CAS Number: 1792181-33-9
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2023-03-05 06:52:53
Modify Date: 2025-11-28 17:45:31
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1].

Name	Vunakizumab

Description	Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
References	[1]. Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95-102.

No Any Chemical & Physical Properties